Minor cannabinoids show ‘promising anti-cancer’ effects, finds study
CBG, CBC, CBN, and CBDV have shown promise as anti-cancer agents in the treatment of blood cancer.
24th July 2024
By Sarah Sinclair
Minor cannabinoids CBG, CBC, CBN, and CBDV have shown promise as anti-cancer agents in the treatment of blood cancer.
Cannabinoids are now widely prescribed to palliative cancer patients to help manage symptoms, as well as the side-effects of conventional treatments such as chemotherapy.
They have also shown potential in the treatment and reduction of cancer itself, such as reducing tumour growth, however, more research is needed to determine exactly which cannabinoids are effective in targeting which tumours.
And while to date, much research has focused on CBD and THC, a new study suggests minor cannabinoids also present in the Cannabis Sativa L. plant also demonstrate anti-cancer properties.
Researchers investigated behind a new study have identified anti-cancer effects of cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV) on a multiple myeloma, a type of bone marrow cancer.
Multiple myeloma usually affects more than one area of the body, such as the spine, skull, pelvis and ribs. There is currently no cura, and although some people live with the diagnosis for many years, patients may become resistant to all available treatments.
READ MORE: Cannabis and cancer: everything you need to know
The researchers examined the cytotoxic activity of CBG, CBC, CBN, and CBDV in vitro in MM cells, their effect in modulating MM cells invasion toward bone cells and the bone resorption.
According to the results, they found that these compounds ‘inhibited MM cell growth, in a dose dependent manner’, with CBN, and CBDV identified as the most efficacious in reducing cell viability.
CBG, CBC, CBN, and CBDV also ‘reduced the invasion of MM cells toward osteoblasts cells’–osteoblasts are cells which form new bones and add growth to existing bone tissue–and bone resorption in vitro, while CBN was found to reduce in vivo tumour mass.
Previous studies support the findings that cannabinoids can reduce tumour growth in vivo and CBG, in particular, have been shown to decrease tumour growth in a mouse model of melanoma.
“Together, our results suggest that CBG, CBC, CBN, and CBDV can be promising anticancer agents for MM, due to their cytotoxic effects on MM cell lines and, for CBN, in in vivo xenograft mouse model of MM, and due to their beneficial effect on the bone in terms of reduction of MM cells invasion toward the bone and bone resorption (mainly CBG and CBN), the authors conclude.
“Further study is needed to better understand how phytocannabinoids work, as well as to better investigate their effects in vivo.”
Related Topics: Cancer CBC CBDV CBG CBN Featured minor cannabinoids
CBG found to reduce anxiety and enhance memory in clinical trial
Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women’s health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag
Recent Articles
- How much does medical cannabis cost in the UK? Releaf’s price plans explained
- Blue Light Card holders to benefit from more affordable medical cannabis
- The tipping point? UK cannabis clinics urged to clean up ‘concerning’ prescribing practices
- UK medical cannabis cards – what you need to know
- Transform prepares to launch UK cannabis legalisation campaign
- Medical cannabis for elderly patients: everything you need to know